Cabozantinib and apixaban: an hitherto unreported interaction

Daniele Santini†, Fabrizio Citarella†, Bruno Vincenzi†, Marco Russano†, Giuseppe Tonini† and Marco Stellato*†

Abstract
The use of direct oral anticoagulant in cancer patients is an emerging issue, which seems to be an alternative to low molecular weight heparin. Every year several new drugs are approved as anticancer treatment with possible drug-drug interaction with other drugs such as oral anticoagulant. We describe, for the first time, a case of neutropenia and thrombocytopenia in a patient in treatment with cabozantinib, a novel anticancer treatment used in metastatic renal cell carcinoma, and apixaban with promptly resumption of the toxicity after the interruption of cabozantinib. This case suggest a possible interaction between these two pharmaceutical agents, which merit caution considering the spreading of the two drugs.

Keywords: Cabozantinib, Metastatic renal cell carcinoma (mRCC), Drug–drug interaction, Apixaban, Cytochrome P450 (CYP 450), P-glycoprotein (P-Gp)

To the editor
The management of anticoagulant therapy in cancer patients is an emerging issue because it potentially involves drug–drug interactions (DDI). Recently, last generation direct oral anticoagulants (DOACs) demonstrated to be an available alternative compared to low molecular weight heparin (LMWH) in cancer patients [1]. Two trials published on The New England Journal of Medicine demonstrated that apixaban and rivaroxaban reduce the incidence of thromboembolic events in cancer patients. These data stimulated debate about the use of DOACs [2, 3].

Indeed, the use of these drugs in clinical practice is growing and this may lead to possible DDI with several anticancer drugs. We report the case of a man, affected by metastatic renal cell carcinoma (mRCC), intermediate risk score according to International mRCC Database Consortium (IMDC) and chronic kidney disease (CKD, 3b stage). He began treatment with Cabozantinib while he was taking apixaban prescribed 18 months before due to inferior vena cava thrombosis. The patient discontinued cabozantinib administration after 20 days from the start due to a Grade 3 thrombocytopenia (45/ml platelets as nadir) and a Grade 4 neutropenia with a 30/ml neutrophils as nadir.

No other hematological toxicities were reported after changing anticoagulant therapy from apixaban to Nadroparin calcium, with no dose reductions or schedule modifications performed for cabozantinib. Up to date, 2 months after anticoagulant shift, the patient has completed 3 months of cabozantinib therapy and no hematological toxicity was subsequently reported.

Interaction between apixaban and Cabozantinib was suspected.

Cabozantinib is a novel oral multikinase inhibitor including RET, MET, KIT, AXL and VEGFR [4]. METEOR trial demonstrated a longer OS and PFS of this drug compared to everolimus leading to the approval of cabozantinib tables in mRCC and changing, so far, the therapeutic scenario [5].

Interactions between cabozantinib, warfarin and dabigatran [6], but never for apixaban, have been reported. Cabozantinib is mainly eliminated via biliary excretion while urinary excretion is exclusively for its metabolites [6]. Moreover, it is a substrate for Cytochrome P4503A4...
(CYP3A4), (with biotransformation in less active metabolites), and a P-glycoprotein (P-gp) inhibitor [6].

About 20% of apixaban undergoes P450 Cytochromes metabolism (mainly via the same CYP3A4), while 30% of the drug is eliminated via urinary excretion. P-gp seems to be involved [7].

We hypothesize that the alterations in cabozantinib pharmacokinetics might have exacerbated the reported hematological toxicity. An excess in free plasma cabozantinib concentration, potentially responsible for hematological toxicity, may be related to a reduction in CYP3A4 bioavailability/activity mainly saturated by circulating apixaban. In addition, CKD was suspected to have been responsible for further apixaban excess and subsequent CYP3A4 saturation. We suppose that these two drugs could interact modifying the pharmacokinetic profile of cabozantinib and amplifying its side effects with the empower of CKD. The clinical scenario described arises the question if this side effect is limited to cabozantinib or could be expectable with other TKI. It is reasonable to assume that this potential pharmacological interaction could be possible for other TKI so that the combination of these different drugs deserve caution. In conclusion, this is the first evidence in literature of a serious hematological toxicity during cabozantinib and apixaban co-administration giving relevance to our report.

Abbreviations
DDI: drug–drug interaction; DOACs: direct oral anticoagulants; LMWH: low molecular weight heparin; mRCC: metastatic renal cell carcinoma; CKD: chronic kidney disease; CYP3A4: cytochrome P4503A4; P-gp: P-glycoprotein.

Acknowledgements
None.

Authors’ contributions
All authors read and approved the final manuscript.

Funding
No founding was required.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
Ethics approval by the ethics committee was waived because it was not a clinical trial or a research but a report of a case of drug–drug interaction. Patient gave his consent to the publication of this letter.

Consent for publication
Patient gave his consent to publish his data.

Competing interests
The authors declare that they have no competing interests.

Received: 17 July 2019 Accepted: 4 September 2019
Published online: 11 September 2019

References
1. Ay C, Beyer-Westendorf J, Pabinger I. Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants. Ann Oncol. 2019;30:897–907.
2. Carrier M, Abou-Nassar K, Mallick R, et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019;380:711–9.
3. Khorana AA, Soff GA, Kakkar AK. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med. 2019;380:720–8.
4. Qin S, Li A, Yi M. Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. Hematol Oncol. 2019;12(1):27.
5. Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015. https://doi.org/10.1056/NEJMoa1510016.
6. CABOMETYX (cabozantinib) UK summary of product characteristics. https://www.medicines.org.uk/emc/medicine/32431. Accessed 23 Oct 2017.
7. Eliquis [package insert]. Princeton: Bristol-Myers Squibb Company; 2012.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.